Hippocratic AI · 2 days ago
General Evaluator, Patient Services / Access Specialist (non-clinical)
Hippocratic AI is a leader in healthcare AI, focusing on creating safe, patient-facing clinical agents. The Patient Access Evaluator will review and assess Voice AI interactions related to patient benefits and access, ensuring accurate and helpful guidance is provided to users.
Artificial Intelligence (AI)Foundational AIGenerative AIHealth CareInformation Technology
Responsibilities
Listen to and evaluate Voice AI calls related to insurance coverage, benefits explanations, prior authorization basics, affordability, and access next steps
Assess accuracy, clarity, tone, and appropriate escalation handling
Identify misinformation, patient confusion, or incomplete guidance related to benefits or access
Score calls using defined rubrics and provide clear, actionable feedback
Flag potential risks impacting patient understanding, access, or follow-through
Qualification
Required
2–5+ years of experience in patient access, benefits investigation, reimbursement support, or financial navigation
Direct experience communicating with patients about insurance coverage, benefits, or affordability
Strong written and verbal communication skills
Ability to make clear, precise judgment calls when evaluating AI performance
Fluency in English
Reliable access to a computer and high-speed internet
Preferred
Experience supporting specialty therapies or complex benefit structures
Familiarity with hub services, patient support programs, or access-related call workflows
Experience using access or reimbursement tools (e.g., CRMs, hub platforms, call review systems)
Fluency in an additional language
Exposure to digital health or AI-enabled support tools
Company
Hippocratic AI
Hippocratic AI is a healthcare technology company that develops safety-focused large-language models for medical applications.
Funding
Current Stage
Growth StageTotal Funding
$402MKey Investors
AvenirKleiner PerkinsNVentures
2025-11-03Series C· $126M
2025-01-09Series B· $141M
2024-09-19Series A· $17M
Recent News
generalcatalyst.com
2026-01-05
Company data provided by crunchbase